AZD8701, an Antisense Oligonucleotide Targeting FOXP3 Mrna, As Monotherapy and in Combination with Durvalumab: Phase I Trial in Patients with Advanced Solid Tumors.
Lillian L Siu,Sophie Postel-Vinay,Rafael Villanueva-Vázquez,Guillermo de Velasco,Eduardo Castanon Alvarez,Christos E Kyriakopoulos,Melissa Johnson,Kaïssa Ouali,Stephen McMorn,Helen K Angell,Felicia Ng,Shashank Saran,Mahdiye Bayat,Teresa Collins,Archana Roy,Arthur W Lambert,Song Cho,Neil Miller,Michele Petruzzelli,John Stone,Christophe Massard
Clinical cancer research an official journal of the American Association for Cancer Research（2025）
